Programmed cell death 6, a novel p53-responsive gene, targets to the nucleus in the apoptotic response to DNA damage

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1788-1794

  Suzuki, Kazuho ^a   Dashzeveg, Nurmaa ^a   Lu, Zheng Guang ^a   Taira, Naoe ^a   Miki, Yoshio ^a   Yoshida, Kiyotsugu ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DNA SEQUENCE; GENE; GENE ACTIVITY; GENE CONTROL; GENE LOCATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGRAMMED CELL DEATH 6 GENE; PROMOTER REGION; PROTEIN CLEAVAGE;

AMINO ACID SEQUENCE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; DNA DAMAGE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867234459     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02362.x     Document Type: Article

References (44)

1. Birch JM, Blair V, Kelsey AM et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998; 17: 1061-8.
2. Olivier M, Goldgar DE, Sodha N et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63: 6643-50.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
4. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
5. Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235-46.
6. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: a001883.
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
8. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002; 8: S38-42.
9. Yoshida K, Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 2010; 101: 831-5.
10. Yoshida K. Nuclear trafficking of pro-apoptotic kinases in response to DNA damage. Trends Mol Med 2008; 14: 305-13.
11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
12. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
13. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
14. Hermeking H, Lengauer C, Polyak K et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
15. Lindsten T, Ross AJ, King A et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-99.
16. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-9.
17. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006; 45: 409-15.
18. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003; 10: 404-8.
19. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 2010; 20: 14-24.
20. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004; 95: 7-11.
21. Levine AJ. p53 the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
22. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 2007; 25: 725-38.
23. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 2003; 7: 249-57.
24. Wei MC, Zong WX, Cheng EH et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.
25. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002; 4: 842-9.
26. Oda E, Ohki R, Murasawa H et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-8.
27. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-94.
28. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
29. 2+-binding proteins with five EF-hand motifs. Biochem J 1997; 328: 718-20.
30. 2+-binding modulator protein involved in cell proliferation and in cell death. Biochim Biophys Acta 2002; 1600: 68-73.
31. Vito P, Lacana E, D'Adamio L. Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 1996; 271: 521-5.
32. Tarabykina S, Moller AL, Durussel I, Cox J, Berchtold MW. Two forms of the apoptosis-linked protein ALG-2 with different Ca(2+) affinities and target recognition. J Biol Chem 2000; 275: 10514-8.
33. Chatellard-Causse C, Blot B, Cristina N, Torch S, Missotten M, Sadoul R. Alix (ALG-2-interacting protein X), a protein involved in apoptosis, binds to endophilins and induces cytoplasmic vacuolization. J Biol Chem 2002; 277: 29108-15.
34. Wu Y, Pan S, Luo W, Lin SH, Kuang J. Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells. Oncogene 2002; 21: 6801-8.
35. 2+-binding protein ALG-2 is recruited to endoplasmic reticulum exit sites by Sec31A and stabilizes the localization of Sec31A. Mol Biol Cell 2006; 17: 4876-87.
36. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005; 7: 278-85.
37. Yoshida K, Liu H, Miki Y. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 2006; 281: 5734-40.
38. Yoshida K, Wang HG, Miki Y, Kufe D. Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J 2003; 22: 1431-41.
39. Hoj BR, la Cour JM, Mollerup J, Berchtold MW. ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell death. Biochem Biophys Res Commun 2009; 378: 145-8.
40. la Cour JM, Hoj BR, Mollerup J, Simon R, Sauter G, Berchtold MW. The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol 2008; 1: 431-9.
41. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-49.
42. Cokol M, Nair R, Rost B. Finding nuclear localization signals. EMBO Rep 2000; 1: 411-5.
43. Rao RV, Poksay KS, Castro-Obregon S et al. Molecular components of a cell death pathway activated by endoplasmic reticulum stress. J Biol Chem 2004; 279: 177-87.
44. Park SH, Lee JH, Lee GB et al. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-kappaB pathways. Cell Signal 2012; 24: 726-33.